newsfilter
← Latest News
GlobeNewswire·

Nabriva Therapeutics Reports Third Quarter 2021 Financial Results and Provides a Corporate Update

-Revenues of $8.9 million increased 8% sequentially versus Q2 2021- -SIVEXTRO Net Sales & Prescriptions both grew 14% sequentially versus Q2 2021- -Cash runway extended to substantially through Q2 2022- -Conference call today at 4:30 p.m. Easter